We independently review everything we recommend. When you buy through our links, we may earn a commission. Learn more› By Doug Mahoney Doug Mahoney is a writer covering home-improvement topics, ...
Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...
Nasdaq provides company’s SEC filings, which are financial statements and reports filed electronically with the U.S. Securities and Exchange Commission (SEC) by Quotemedia. The SEC requires all ...
Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...
来自MSN
REPL stock on track for worst drop in nearly 7 months ahead of FDA decision on skin cancer drug
・The FDA issued a complete response letter regarding the application for RP1 in combination with Nivolumab for the treatment of advanced melanoma in late July. ・Following months of engagement between ...
As shares of Replimune Group (REPL) hit an all-time low on Monday of $1.50 following the US FDA's rejection of its lead asset, the melanoma drug RP1, the Street is also turning negative on the company ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果